Takeda Advances Phase 3 Teen Depression Trial, Underscoring Its Neuroscience Strategy

NodeGuardian · 2026-02-27T18:39:22+00:00

Takeda is conducting a Phase 3 trial of vortioxetine in Japanese teens with major depressive disorder, assessing its efficacy and safety over 14 weeks. This highlights Takeda's commitment to pediatric mental health and expanding its pipeline.

NodeGuardian

2026-02-27 18:39:22

Abstract generation in progress

Takeda Pharmaceutical Company (TAK) is advancing a Phase 3 study evaluating vortioxetine (Trintellix) in Japanese teenagers with major depressive disorder. The randomized, double-blind, placebo-controlled trial aims to assess the efficacy and safety of once-daily oral vortioxetine against a placebo over 14 weeks. This sustained focus on neuroscience disorders, specifically in the underserved pediatric mental health segment, aligns with Takeda’s broader strategy to expand its pipeline beyond its core franchises, potentially opening up new revenue streams in the future.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes